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The fate of infected macrophages is a critical aspect of immunity to mycobacteria. By
depriving the pathogen of its intracellular niche, apoptotic death of the infected macro-
phage has been shown to be an important mechanism to control bacterial growth. Here,
we show that IL-17 inhibits apoptosis of Mycobacterium bovis BCG- or Mycobacterium
tuberculosis-infected macrophages thus hampering their ability to control bacterial
growth. Mechanistically, we show that IL-17 inhibits p53, and impacts on the intrinsic
apoptotic pathway, by increasing the Bcl2 and decreasing Bax expression, decreasing
cytochrome c release from the mitochondria, and inhibiting caspase-3 activation. The
same effect of IL-17 was observed in infected macrophages upon blockade of p53
nuclear translocation. These results reveal a previously unappreciated role for the IL-17/
p53 axis in the regulation of mycobacteria-induced apoptosis and can have important
implications in a broad spectrum of diseases where apoptosis of the infected cell is an
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introduction
Mycobacterium tuberculosis is an intracellular pathogen responsible for the death of ~1.5 million 
people every year (1). Macrophages are the first cells to be infected by M. tuberculosis and provide 
the bases for a sequence of microbicidal actions which contain the infection (2). A growing body 
of evidence points to the ability to manipulate apoptosis, a form of programed cell death, as an 
important determinant of mycobacterial pathogenesis, although conflicting results support either 
inhibition or activation of apoptosis as a virulence mechanism (3, 4). Indeed, several studies suggest 
that the induction of apoptosis is unique to avirulent strains of mycobacteria, acting as a mechanism 
to prevent the spread of infection, by allowing antigen cross-presentation in favor of the host (5–8). 
In contrast, other authors argue that only virulent strains of M. tuberculosis induce apoptosis of 
infected cells (3, 9, 10). These apparent discrepancies may be due to experimental conditions, with 
in vivo data suggesting that both apoptosis and necrosis of infected cells occur, depending on the 
anatomical location and timing of infection (3).
Among the factors dictating the fate of mycobacterially infected cells is the cytokine composition of 
the extracellular milieu. Specifically, tumor necrosis factor (TNF)-α induces while interleukin (IL)-10 
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inhibits apoptosis of the mycobacterially infected macrophages 
(11, 12). Although M. tuberculosis-infected macrophages are 
exposed to many other cytokines produced during the immune 
response, the impact of these cytokines on apoptosis of infected 
cells remains unclear. In this context, IL-17 is interesting, as this 
cytokine produced by T helper (Th)17 cells during chronic viral 
infection leads to the upregulation of the pro-survival proteins 
Bcl-xl and Bcl2 resulting in reduced apoptosis of infected cells; 
this, in turn, contributes to viral persistence and pathogenesis 
(13). IL-17 was also shown to promote survival of airway mac-
rophages upon allergen-induced airway inflammation (14) and 
of fibroblast-like synoviocytes during chronic inflammation, 
through signal-transducer and activator of transcription protein 
(STAT)-3 activation (15). Moreover, IL-17 and Th17 cells have 
been linked to cancer, although both pro- and anti-tumorigenic 
activities have been ascribed to this cytokine (16–18).
The evidence supporting a role for IL-17 in modulating 
the apoptotic pathway, together with the early production of 
IL-17 following M. tuberculosis infection (19), prompted us to 
investigate the role of IL-17 in the modulation of apoptosis in 
mycobacterially infected macrophages. Using mouse primary 
bone marrow-derived macrophages (BMDM) infected with 
M. tuberculosis or M. bovis BCG, we show that in the presence 
of IL-17 macrophages are more permissive to Mycobacterium 
growth consistent with a reduced apoptotic death of the infected 
macrophages. Mechanistically, we show that IL-17 interferes with 
the master regulator of apoptosis p53, alters the transcriptional 
profile of Bax and Bcl2 and inhibits cytochrome c release.
Materials and Methods
animals
Eight- to 12-week-old female C57BL/6 mice obtained from 
Charles River (Barcelona, Spain) were used. All experimental pro-
tocols involving mice were performed according to the European 
Union Directive 86/609/EEC, and previously approved by the 
national authority Direção Geral de Alimentação e Veterinária.
reagents and Bacteria
Recombinant mouse IL-17A (R&D Systems) and the specific 
p53 chemical inhibitor cyclic pifithrin-alpha (PFT-α; Sigma) 
were used at 100 ng/mL and 30 μM, respectively, based on a dose 
response curve (data not shown). M. bovis BCG Pasteur or M. 
tuberculosis H37Rv (a kind gift of Pere-Juan Cardona, Barcelona) 
stocks were prepared as previously described (20).
culture of Mouse BMDM
Bone marrow-derived macrophages were generated and 
infected at a multiplicity of infection (MOI) of two bacteria 
per macrophage as described (20, 21). Cells were treated as 
described in the figure legends. To determine the number of 
viable bacteria, macrophage cultures were lysed with 0.1% 
saponin and the bacterial suspensions were serially diluted and 
plated onto 7H11 agar medium. Bacterial colony formation 
was counted after 3 weeks of incubation at 37°C. To determine 
the viability of BMDM in culture, the medium was aspirated 
and the adherent cells incubated for 10  min with 2.5  mg/mL 
of protease type XXV (Sigma) to digest any dead cells. Next, 
cetrimide (Sigma) was added to lyse the viable cells and a 
suspension of the cell nuclei was obtained and counted using 
a Neubauer chamber.
nitrites Quantification
Nitrite production by macrophages was determined by the Griess 
assay (22).
cytokine analysis by elisa
Tumor necrosis factor and IL-10 were measured in the culture 
supernatants using commercial kits (eBioscience) according to 
the manufacturer’s specifications.
immunofluorescence
Bone marrow-derived macrophages were cultured in cover-slips 
placed at the bottom of the 24-well incubation plates, infected, 
and treated according to the description in the figure legends. 
At specific time points after infection, cells were fixed in 2% 
buffered paraformaldehyde (PFA) and probed with rabbit anti-
human/mouse specific for active caspase 3 (R&D Systems) 
or anti-mouse specific for p53 (Cell Signaling), followed by 
Alexa Fluor 594-conjugated goat anti-rabbit or anti-mouse IgG 
(Molecular Probes), respectively. 4′,6-Diamino-2-phenylindole 
hydrochloride (DAPI) (Molecular Probes) was used to detect 
nuclei. Quantification of mean intensity of p53 protein was per-
formed using the regions of interest (ROI) Manager application 
of the ImageJ program, which quantifies the mean intensity of 
selected areas. A total of five different fields for each cover-slip 
was analyzed. The mean intensity was calculated by selecting the 
ROI using the freehand selection tool. The number of caspase-3 
positive cells was determined by acquiring five different fields of 
the cover-slips and counting 300 cells for each condition. The 
percentage of caspase-3 positive cells was calculated by dividing 
the number of caspase-3 positive cells by the total number of cells.
Quantitative real-Time Pcr analysis
Total RNA from cultured BMDM was extracted and reverse-
transcribed as described previously (20). Mouse p53, Bcl2, 
and Bax gene mRNA expression was quantified using specific 
primer probes (ABI) (Mm01731287_m1; Mm00477631_m1 and 
Mm00432051_m1, respectively) and normalized to the hypoxan-
thine guanine phosphoribosyl transferase (HPRT) mRNA levels 
(Mm00446968_m1).
cytochrome c release
The protocol was performed as previously described (23). 
Briefly, cells were permeabilized with digitonin buffer (50  μg/
mL of digitonin in PBS with 100  mM KCl), fixed in 2% (w/v) 
buffered-PFA in PBS (pH 7.4), for 30 min at room temperature, 
rinsed, resuspended in PBS, and stored at 4°C. When all time 
points had been collected, 106 cells were incubated in blocking 
buffer for 1  h, at room temperature, stained with mouse puri-
fied anti-cytochrome c antibody (BD Pharmingen) overnight at 
4°C, followed by the secondary anti-mouse IgG1-PE antibody 
(BioLegend) for 20 min. Stained cells were run in a LSRII flow 
cytometer and analyzed with FlowJo software (Tristar).
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Western Blot
Protein extracts were prepared, resolved in 12% SDS-PAGE, and 
western blot performed as described previously (24). Primary 
FigUre 1 | il-17 promotes growth of M. bovis Bcg and M. tuberculosis in infected BMDM. BMDM were infected with M. bovis BCG (A) or with M. 
tuberculosis (B) and treated (+) or not (−) with IL-17. (a) Four days post-infection, the bacterial load was assessed. Fifty out of 50 independent experiments are 
represented in the graph. The mean-fold increase in CFUs induced by IL-17 is 0.4 ± 0.2 log. (B) Three days post-infection, the bacterial load was assessed. Eleven 
out of 11 independent experiments are represented in the graph. The mean-fold increase in CFUs induced by IL-17 is 0.28 ± 0.18 log. Significance determined by 
Student’s t test (***p < 0.001). BMDM were left uninfected or infected with M. bovis BCG and treated (+) or not (−) with IL-17. (c) Nitrites production by was 
measured in the supernatants of the cultures by the Griess method. (D) The mRNA expression of LRG47 was quantified by real-time PCR using the primers (sense 
5′-CTCTGGATCAGGGTTTGAGGAGTA-3′; anti-sense 5′-GGAACT GTGATGGTTTCATGATA-3′) and probes (5′-LCred640-AGGTCCACAGACAGCGTCACTCGG
-P-3′; 5′-AACCAGAGAGCCTCACCAGG GAGCTGA-FL-3′) and normalized to HPRT. The fold increase of LRG47 mRNA expression over NI control was calculated. 
Represented are the mean ± SE of three independent experiments. (e,F) At different time points post-infection, supernatants were harvested and the production of 
TNF (e) and IL-10 (F) assessed by immunoassay. Data point represents a mean of n = 6. Results are from one representative out of three independent experiments.
antibodies were actin (JLA20, developed by Lin JJC and obtained 
from the Developmental Studies Hybridoma Bank, developed 
under the auspices of the National Institute of Child Health 
FigUre 2 | il-17 inhibits the upregulation of p53 observed during 
infection of BMDM with M. bovis Bcg. BMDM were infected with M. 
bovis BCG and treated (+) or not (−) with IL-17. (a) At the indicated time 
points, the expression of p53 was assessed by quantitative real-time PCR 
and normalized against HPRT. The fold increase of p53 mRNA expression 
over non-infected (NI) control was calculated. (B) Two days post-infection 
p53 levels were assessed by immunofluorescence and the fold increase of 
p53 mean intensity of cells over NI control calculated using ROI Manager 
application of the ImageJ program. The CFU controls for the represented 
experiments are plotted in Figure 1a. Representative images used for the 
calculations are in Figure S1 in Supplementary Material. Represented are the 
mean ± SE of three independent experiments each of them performed for 
triplicate conditions. Significance determined by Student’s t test 
(***p < 0.001).
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and Human Development and maintained by The University of 
Iowa, Department of Biology), Bax, Bcl2, and caspase-3 (all Cell 
Signaling). Secondary antibodies were from Southern Biotech or 
Santa Cruz. The same membrane was used to detect Bax and Bcl2. 
Total and cleaved caspase-3 was detected in the same membrane. 
Chemiluminescence detection system SuperSignal West Femto 
(Thermo Scientific) and the Universal Hood II (Bio-Rad) were 
used as a detection system. Band intensity was quantified using 
QuantityOne (Bio-Rad).
statistical analysis
The results are given as mean ± SE. Statistical significance was 
calculated by using Student’s t test, or one-way ANOVA with 
Tukey’s post-test. Values of p ≤ 0.05 were considered significant.
results
il-17 renders Macrophages More Permissive to 
Mycobacterium growth
IL-17 production is induced upon M. bovis BCG and M. tubercu-
losis infection, with γδ T cells as the major cellular source during 
the early stage of the infection (19, 25). However, the impact of 
this cytokine on mycobacterially infected macrophages remains 
to be investigated. To address this, mouse primary BMDM were 
infected with M. bovis BCG in the presence or absence of IL-17 
and, 4 days after infection, the number of viable bacteria present 
in each condition was determined. A significantly higher num-
ber of viable bacteria were consistently found in macrophages 
stimulated with IL-17 (Figure 1A). Importantly, this effect was 
not specific for M. bovis BCG as the ability of macrophages to 
control M. tuberculosis was also significantly hampered by IL-17 
(Figure 1B). These data suggest that IL-17 renders mycobacteri-
ally infected macrophages more permissive to bacterial growth. 
Notably, IL-17 did not interfere with basic macrophage microbi-
cidal mechanisms, such as nitric oxide production (Figure 1C) 
or LRG47 expression, a marker for phagolysosome formation 
(Figure 1D). Since TNF and IL-10 play important roles on the 
regulation of apoptosis in mycobacterially infected macrophages 
(11, 12), a possible regulation of these molecules by IL-17 was 
next investigated. However, IL-17 did not impact the production 
of TNF (Figure 1E) or of IL-10 (Figure 1F) observed in mac-
rophages upon M. bovis BCG infection.
il-17 interferes with p53 in Mycobacterially 
infected Macrophages
Activation of the apoptotic pathway is thought to be a host defen-
sive mechanism against mycobacterial pathogens (26). IL-17 has 
been shown to modulate apoptosis in viral infection (13) and in 
cancer (17, 18), but its role in the context of mycobacterial infec-
tion inducing apoptosis has not been addressed yet. Since IL-17 
has been shown to down-regulate the activity of the apoptosis 
master regulator p53 (27, 28), we investigated whether IL-17 is 
able to modulate p53 in mycobacterially infected macrophages. 
While an upregulation of p53 transcription upon infection with 
M. bovis BCG was observed 48  h post-infection, this was not 
affected by the presence of IL-17 (Figure  2A). In contrast, the 
increase in p53 protein levels as measured by immunofluores-
cence, observed as early as 2 days post-M. bovis BCG infection, 
was abrogated by IL-17 (Figure 2B; Figure S1 in Supplementary 
Material). These data show that IL-17 down-regulates p53 at the 
protein level, suggesting that it may interfere with apoptosis of 
infected cells. Further, this interference may be the pathway by 
which IL-17 impacts the bacterial growth control.
il-17 inhibits apoptosis in Mycobacterially 
infected Macrophages
Given that IL-17 modulated p53 protein, this cytokine could 
impact on the induction of apoptotic programed cell death, an 
important antimicrobial mechanism operating upon mycobacte-
rial infection (26). Thus, the role of IL-17 on the survival of infected 
macrophages was investigated. First, the viability of BMDM at 
different times post-infection with M. bovis BCG was measured. 
FigUre 3 | il-17 inhibits macrophage apoptosis induced by mycobacterial infection. BMDM were infected with M. bovis BCG in the presence or absence 
of IL-17 as indicated. (a) On days 2 and 7 post-infection, the cell viability was assessed by enumerating nuclei. (B) On days 2, 4, and 5 post-M. bovis BCG 
infection, activation of caspase-3 was assessed by immunofluorescence. (c) At 48 or 72 h post-M. bovis BCG infection, full-length and cleaved forms of caspase-3 
protein were determined by western blot. (D,e) At 24 or 48 h post-M. bovis BCG infection, the Bcl2 and Bax mRNA or at 48 or 72 h post-M. bovis BCG infection, 
the protein were determined by real-time PCR or western blot respectively.(F) Cytochrome c release from the mitochondria was determined 2 days post-infection by 
flow cytometry. The fold increase of cytochrome c released over NI control was calculated for each independent experiment. Representative images used for (a) 
and (B) are in Figure S2 in Supplementary Material. Represented are the mean ± SE of four independent experiments. Significance determined by one-way ANOVA 
(a,B) or Student’s t test (D–F) (*p < 0.05; **p < 0.01; ***p < 0.001).
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As expected, the survival of infected macrophages decreased 
over time as compared to non-infected (NI) cells. However, the 
presence of IL-17 increased the survival of infected macrophages 
to levels similar to those of NI cells (Figure 3A; Figure S2A in 
Supplementary Material). Next, BMDM were infected with M. 
bovis BCG in the absence or presence of IL-17 and the activation 
of caspase-3, a major apoptotic effector caspase, was determined 
by immunofluorescence microscopy. We found that the presence 
of IL-17 resulted in a reduction in the percentage of caspase-
3-positive macrophages through day 5 of infection with M. bovis 
BCG (Figure  3B; Figure S2B in Supplementary Material) or 
with M. tuberculosis (Figure S2C in Supplementary Material). 
Additionally, and in line with the immunofluorescence data, we 
observed a decrease in the protein levels of activated (cleaved) 
caspase-3 upon addition of IL-17 to BCG-infected macrophages, 
as determined by western blot (Figure 3C). Since our previous 
data (Figure 2) showed that IL-17 reduced p53 protein and since 
p53 is a master regulator of pro- and anti-apoptotic molecules 
(29), namely Bax and Bcl2, we next explored the impact of 
IL-17 on these molecules. Upon infection with M. bovis BCG, 
the transcription of Bcl2 was not much affected when compared 
to NI cells, whereas that of Bax was significantly increased 
(Figure 3D). In the presence of IL-17, a marked increase of Bcl2 
transcription accompanied by a decrease of Bax mRNA was 
observed (Figure 3D). The increased Bcl2 transcription observed 
in the presence of IL-17 was confirmed at the protein level, as 
measured by western blot (Figure 3E). In contrast, addition of 
IL-17 did not affect the amount of Bax protein (Figure 3E). In 
all, in the presence of IL-17, the ratio of Bcl2/Bax proteins was 
significantly increased, suggesting an anti-apoptotic activity for 
IL-17. The ratio of Bcl2 to Bax is an important component of the 
intrinsic apoptotic pathway that regulates the permeabilization 
of the outer mitochondrial membrane, and thereby the release 
of cytochrome c. Therefore, the release of cytochrome c in M. 
bovis BCG-infected macrophages in the presence or absence of 
IL-17 was determined. We found that cytochrome c release was 
observed upon infection of macrophages, in line with the activa-
tion of the intrinsic apoptotic pathway (Figure 3F). Further, it 
was clear that cytochrome c release induced by BCG was abro-
gated in the presence of IL-17 (Figure 3F). These data suggest 
that IL-17 inhibits the intrinsic apoptotic pathway by altering the 
Bcl2/Bax ratio and the release of cytochrome c.
Modulation of p53 activity impacts 
Mycobacterial growth in Macrophages
As IL-17 decreases the capacity of macrophages to limit bacterial 
growth (Figure 1), reduces availability of p53, and limits apop-
tosis in mycobacterially infected macrophages, we hypothesized 
that IL-17 impacts mycobacterial growth via modulation of p53 
activity. To test this hypothesis, we chemically inhibited the 
nuclear translocation of p53 during infection of macrophages 
with M. bovis BCG. Blocking the nuclear activity of p53 led to 
a significant decrease on the percentage of caspase 3-positive 
cells (Figure  4A and Figure S3A in Supplementary Material) 
accompanied by a significant increase in the number of bacteria 
(Figure 4B). Also, we observed that PFT-α addition to M. bovis 
BCG-infected macrophages increased the expression of the Bcl2, 
whereas that of Bax was not significantly altered (Figure  4C). 
The effect of PFT-α in increasing the number of bacteria was not 
further potentiated by IL-17 (Figure 4D), suggesting that p53 is 
a downstream mediator of IL-17 in this experimental setting. All 
our data show that IL-17, by modulating cell survival, impacts 
mycobacterial control by macrophages.
FigUre 4 | Blockade of p53 impairs apoptosis of infected 
macrophages and bacterial growth control. BMDM were infected with 
M. bovis BCG in the presence (+) or absence (−) of the p53 inhibitor PFTα. 
Four days post-infection (a) caspase-3 activation was assessed by 
immunofluorescence and (B) the bacterial load was assessed as indicated 
before. Representative images used for the calculations are in Figure S3 in 
Supplementary Material. (c) At 24 or 48 h post-M. bovis BCG infection, the 
Bcl2 and Bax mRNA was determined by real-time PCR. The fold increase of 
Bcl2 or Bax mRNA over the NI control was calculated for each independent 
experiment. (D) BMDM were left uninfected or infected with M. bovis BCG in 
the presence or absence of IL-17 or of PFTα as indicated. Four days 
post-infection the bacterial load was assessed as indicated before. 
Represented are the mean ± SE of three independent experiments. 
Significance determined by Student’s t test (***p < 0.001).
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Discussion
The importance of apoptosis in infection and of its modulation 
by intracellular pathogens is established. Apoptosis of mycobac-
terially infected cells is an important microbicidal mechanism, 
preventing the spread of the pathogen and promoting antigen 
cross-presentation (26). Whether the virulence of the infecting 
mycobacterial strain plays a role in promoting or evading apop-
tosis of the host cells is still a matter of debate (3, 4). However, it 
is clear that understanding the mechanisms underlying the fate 
of M. tuberculosis-infected macrophages is of critical importance, 
as therein may lay the potential to intervene. The programed cell 
death pathways in mycobacterially infected cells are regulated 
by host-encoded molecules, including eicosanoids (5, 6) and 
cytokines (11, 12). Our study adds a new layer to the complexity 
of this regulation, by reporting a pathway wherein IL-17 functions 
as an anti-apoptotic mediator in mycobacterially infected cells 
through its action on p53 and inhibition of the mitochondrial 
apoptotic pathway.
We dissected the early events of the apoptotic pathway 
initiated by mycobacterial infection. Following M. bovis BCG 
infection, p53 transcription occurred and there was an increase 
in the percentage of p53-positive cells, in agreement with 
previous studies (11). This was accompanied by a reduction in 
the Bcl2/Bax ratio, the activation of caspase-3 and an increase 
in cytochrome c release. All these pro-apoptotic events were 
down-regulated by IL-17 activity, placing this cytokine as a novel 
apoptotic modulator in the context of mycobacterial infection. 
Several lines of evidence support a link between IL-17 and apop-
tosis, for example, in the modulation of Fas-Fas ligand induced 
apoptosis in the context of a viral infection (13), of fibroblast-like 
synoviocytes apoptosis, through the activation of STAT-3 (15), 
and in inhibition of p53 transcription in a lymphoma cell line 
(27). As we now show, in the context of mycobacteria infection, 
IL-17 acts by decreasing the levels of p53 protein in M. bovis 
BCG-infected BMDM. This modulation is likely taking place at 
the post-transcriptional level since alterations of p53 transcrip-
tion were not observed in our experimental setting. An important 
control mechanism for p53 regulation is through ubiquitination, 
with several E3 ligases described for p53 (30). Act1, the key 
transducer of IL-17 receptor signaling, is also an E3 ubiquitin 
ligase, which shares conserved residues with those known to 
ubiquitinate p53 and activate its proteasomal degradation (31). 
It is, therefore, tempting to speculate that IL-17 may be promot-
ing the degradation of p53 through proteasome degradation. It 
will be important in future to further dissect the IL-17-driven 
upstream events leading to the observed alterations, particu-
larly those happening immediately after IL-17R triggering. 
Mechanistically, it is possible that the effect of IL-17 in blocking 
apoptosis of the infected cell requires other molecules produced 
during infection. Although the balance between TNF and IL-10 
within mycobacterially infected macrophages is important in 
the occurrence of apoptosis of the infected cell (12), we did not 
observe an impact of IL-17 in the amount of secreted TNF or 
IL-10 produced.
Elucidating the mechanisms by which IL-17-mediates p53 
modulation is central not only in the context of intracellular 
infections, but also considering the fact that several studies 
involving the axis IL-17/p53 in cancer have been undertaken (27, 
28, 32) and that IL-17-based therapies are being developed (33).
acknowledgments
The authors thank the personnel at the ICVS animal house 
facility for excellent animal husbandry. This work has been 
funded by Fundação para a Ciência e Tecnologia, Portugal. 
Project grants: PTDC/SAU-MII/101977/2008 (to AGC), PTDC/
BIA-BCM/102776/2008 (to MS) and HMSP-ICT/0024/2010 
(to RA) and co-funded by Programa Operacional Regional 
do Norte (ON.2  –  O Novo Norte), Quadro de Referência 
Estratégico Nacional (QREN), through the Fundo Europeu de 
Desenvolvimento Regional (FEDER). Personal Grants: SFRH/
BPD/33036/2006 to AC; SFRH/BD/33573/2009 to JBG. AMC is 
supported by Trudeau Institute, Inc. and NIAID PO1 AI46530. 
MS is a FCT Associate Investigator.
supplementary Material
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2015.00498
September 2015 | Volume 6 | Article 4988
Cruz et al. IL-17A inhibits apoptosis of Mycobacterium-infected macrophages
Frontiers in Immunology | www.frontiersin.org
11. Rodrigues MF, Barsante MM, Alves CC, Souza MA, Ferreira AP, Amarante-
Mendes GP, et al. Apoptosis of macrophages during pulmonary Mycobacterium 
bovis infection: correlation with intracellular bacillary load and cytokine 
levels. Immunology (2009) 128:e691–9. doi:10.1111/j.1365-2567.2009.03062.x 
12. Rojas M, Olivier M, Gros P, Barrera LF, Garcia LF. TNF-alpha and IL-10 
modulate the induction of apoptosis by virulent Mycobacterium tuberculosis 
in murine macrophages. J Immunol (1999) 162:6122–31. doi:10.1084/
jem.20082030 
13. Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit 
T cell cytotoxicity in a model of chronic virus infection. J Exp Med (2009) 
206:313–28. doi:10.1084/jem.20082030 
14. Sergejeva S, Ivanov S, Lotvall J, Linden A. Interleukin-17 as a recruitment 
and survival factor for airway macrophages in allergic airway inflammation. 
Am J Respir Cell Mol Biol (2005) 33:248–53. doi:10.1165/rcmb.2004-0213OC 
15. Lee SY, Kwok SK, Son HJ, Ryu JG, Kim EK, Oh HJ, et  al. IL-17-mediated 
Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheu-
matoid arthritis through STAT3 activation. Arthritis Res Ther (2013) 15:R31. 
doi:10.1186/ar4179 
16. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogen-
esis of inflammatory diseases. Cell Signal (2013) 25:2335–47. doi:10.1016/j.
cellsig.2013.07.021 
17. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, et  al. Th17 cells in 
cancer: help or hindrance? Carcinogenesis (2011) 32:643–9. doi:10.1093/
carcin/bgr019 
18. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. 
Nat Rev Immunol (2010) 10:248–56. doi:10.1038/nri2742 
19. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gam-
madelta T cells rather than CD4 T cells during Mycobacterium tuberculosis 
infection. J Immunol (2006) 177:4662–9. doi:10.4049/jimmunol.177.7.4662 
20. Carmona J, Cruz A, Moreira-Teixeira L, Sousa C, Sousa J, Osorio NS, et al. 
Mycobacterium tuberculosis strains are differentially recognized by TLRs with 
an impact on the immune response. PLoS One (2013) 8:e67277. doi:10.1371/
journal.pone.0067277 
21. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, Filho AL, et  al. 
Infection with Mycobacterium ulcerans induces persistent inflammatory 
responses in mice. Infect Immun (2005) 73:6299–310. doi:10.1128/
IAI.73.10.6299-6310.2005 
22. Stuehr DJ, Gross SS, Sakuma I, Levi R, Nathan CF. Activated murine mac-
rophages secrete a metabolite of arginine with the bioactivity of endotheli-
um-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp 
Med (1989) 169:1011–20. doi:10.1084/jem.169.3.1011 
23. Waterhouse NJ, Trapani JA. A new quantitative assay for cytochrome c 
release in apoptotic cells. Cell Death Differ (2003) 10:853–5. doi:10.1038/
sj.cdd.4401263 
24. Gama JB, Ohlmeier S, Martins TG, Fraga AG, Sampaio-Marques B, Carvalho 
MA, et  al. Proteomic analysis of the action of the Mycobacterium ulcerans 
toxin mycolactone: targeting host cells cytoskeleton and collagen. PLoS Negl 
Trop Dis (2014) 8:e3066. doi:10.1371/journal.pntd.0003066 
25. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, Kawakami K, 
et  al. IL-17-mediated regulation of innate and acquired immune response 
against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. 
J Immunol (2007) 178:3786–96. doi:10.4049/jimmunol.178.6.3786 
26. Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X, Gan HX, et  al. 
Apoptosis is an innate defense function of macrophages against Mycobacterium 
tuberculosis. Mucosal Immunol (2011) 4:279–87. doi:10.1038/mi.2011.3 
27. Li Q, Xu X, Zhong W, Du Q, Yu B, Xiong H. IL-17 induces radiation resistance 
of B lymphoma cells by suppressing p53 expression and thereby inhibiting 
irradiation-triggered apoptosis. Cell Mol Immunol (2015) 12:366–72. 
doi:10.1038/cmi.2014.122 
28. Radosavljevic G, Ljujic B, Jovanovic I, Srzentic Z, Pavlovic S, Zdravkovic 
N, et al. Interleukin-17 may be a valuable serum tumor marker in patients 
with colorectal carcinoma. Neoplasma (2010) 57:135–44. doi:10.4149/
neo_2010_02_135 
29. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, et al. Insights 
into p53 transcriptional function via genome-wide chromatin occupancy and 
gene expression analysis. Cell Death Differ (2012) 19:1992–2002. doi:10.1038/
cdd.2012.89 
30. Hock AK, Vousden KH. The role of ubiquitin modification in the regu-
lation of p53. Biochim Biophys Acta (2014) 1843:137–49. doi:10.1016/j.
bbamcr.2013.05.022 
31. Liu C, Qian W, Qian Y, Giltiay NV, Lu Y, Misra S, et al. Act1, a novel U-box 
E3 ubiquitin ligase for IL-17R-mediated signaling. Sci Signal (2009) 2:ra63. 
doi:10.1126/scisignal.2000382 
32. Xu B, Guenther JF, Pociask DA, Wang Y, Kolls JK, You Z, et al. Promotion 
of lung tumor growth by interleukin-17. Am J Physiol Lung Cell Mol Physiol 
(2014) 307:L497–508. doi:10.1152/ajplung.00125.2014 
33. van den Berg WB, McInnes IB. Th17 cells and IL-17 a  –  focus on immu-
nopathogenesis and immunotherapeutics. Semin Arthritis Rheum (2013) 
43:158-170. doi:10.1016/j.semarthrit.2013.04.006 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Cruz, Ludovico, Torrado, Gama, Sousa, Gaifem, Appelberg, 
Rodrigues, Cooper, Pedrosa, Saraiva and Castro. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic prac-
tice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
